MDEA (MDE)

What is MDEA (MDE)?

MDEA, also known as MDE, 3,4-methylenedioxy-N-ethylamphetamine or Eve, is a synthetic ring-substituted amphetamine related to MDMA and MDA. It differs from MDMA by having an ethyl group rather than a methyl group attached to the terminal nitrogen. The compound is often described as an entactogen or empathogen, although its effects also include stimulant and perceptual changes.

Chemistry and relationship to MDMA

MDEA retains the 3,4-methylenedioxy ring found in MDMA and MDA. The difference lies in the nitrogen substituent: MDEA has an N-ethyl group, MDMA has an N-methyl group, and MDA has no additional alkyl group on the terminal nitrogen. This small structural change affects transporter interactions and metabolism, and it means that findings for MDMA cannot automatically be applied to MDEA.

The compound has one chiral centre and can exist as two enantiomers. As with MDMA, the stereoisomers do not contribute equally to every pharmacological effect. The distinction is relevant when interpreting older studies that used racemic mixtures rather than isolated enantiomers.

Pharmacology

MDEA promotes monoamine signalling, particularly through serotonin release and transporter-mediated effects. Its pharmacology overlaps substantially with MDMA, but historical studies and reviews describe differences in the balance between empathogenic, stimulant and perceptual effects. The available receptor and toxicological literature is reviewed in “The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA)”. The methylenedioxy group gives the molecule some mescaline-like properties, while the amphetamine backbone contributes to wakefulness and autonomic stimulation.

MDEA is also metabolized to MDA through N-deethylation. This creates an analytical complication: MDA detected in urine or blood after MDEA exposure may be a metabolite rather than evidence of separate MDA use. Other metabolic pathways include O-demethylenation, catechol methylation and conjugation with sulfate or glucuronic acid.

Human observations and reported effects

MDEA has been examined in human studies, although the research base is much smaller than that for MDMA. A 1992 double-blind, placebo-controlled crossover study in healthy volunteers investigated the effects of MDE on sleep electroencephalography. Other clinical and observational reports describe psychotropic effects broadly similar to MDMA, with feelings of euphoria, emotional openness and sociability. The available studies do not support a precise modern comparison of potency or subjective intensity.

Historical reviews often describe MDEA as less stimulating than MDMA and, in some accounts, more sedating or emotionally subdued. Such distinctions are not consistent enough to define a dependable profile. The compound’s effects vary with the individual, the setting and the material consumed, and older reports often lack modern analytical confirmation.

Physical and perceptual effectsCognitive and emotional effects
  • Stimulation: increased wakefulness and energy are described, though some reports characterize MDEA as less activating than MDMA.
  • Autonomic effects: increased heart rate, blood pressure, sweating and pupil dilation may occur.
  • Physical sensations: jaw tension, muscle tightness and changes in body temperature are reported.
  • Sleep disruption: controlled research has examined changes in sleep architecture following exposure.
  • Physical discomfort: nausea, overheating and restlessness can occur.
  • Empathogenic effects: emotional openness, closeness and increased sociability are described.
  • Euphoria: mood elevation and a sense of well-being may occur.
  • Sensory changes: heightened sensory awareness and mild perceptual alterations are reported.
  • Emotional variability: anxiety, confusion or low mood can occur, particularly during an uncomfortable experience.

These effects are drawn from a mixture of controlled human observations, older clinical reports and user descriptions. They do not establish that MDEA is simply a milder form of MDMA.

Metabolism and toxicology

A human urine study identified MDEA and its phase I and phase II metabolites after administration, including products formed through N-deethylation and O-demethylenation. The 1996 analytical investigation of MDEA and its metabolites is useful for understanding why MDA can appear after MDEA exposure. N-deethylation produces MDA, while O-demethylenation and subsequent methylation or conjugation generate additional metabolites. These pathways are useful in forensic toxicology, particularly when the parent compound is no longer detectable.

Severe intoxications involving MDEA have been documented, including cases of hyperthermia, cardiovascular complications and fatal poisoning. These reports are uncommon and cannot establish the probability of a particular outcome, but they show that MDEA should not be regarded as harmless because its subjective effects are sometimes described as less stimulating than MDMA. A broad review of the pharmacology and toxicology of MDMA and related compounds is available in “The pharmacology and toxicology of ‘ecstasy’ (MDMA) and related drugs”.

MDEA (MDE) Products

Placeholder

MDEA crystals

Price range: $473.00 through $9,135.00
Select options
Placeholder

MDEA pills

Price range: $315.00 through $1,050.00
Select options
Placeholder

MDEA powder

Price range: $473.00 through $9,135.00
Select options

Scientific Data

Identity and Structure

Chemical NameMDEA
Catalog Entity TypeCompound
FormulaC12H17NO2
Molar Mass207.273 g·mol−1
CAS82801-81-8
CAS Numbers and Substance Forms82801-81-8
SynonymsMDEA; MDE; 3,4-Methylenedioxy-N-ethylamphetamine; N-Ethyl-MDA; Eve; EA-1304; EA1304; PAL-192; PAL192; ASR-1003; ASR1003
IUPAC Name1-(1,3-benzodioxol-5-yl)-N-ethylpropan-2-amine
SMILESCCNC(C)Cc1ccc2OCOc2c1

Chemical Identifiers

PubChem CID105039
ChemSpider ID94775
ChEBI IDCHEBI:132237
KEGG IDC22717
UNIIML1I4KK67B
CompTox DTXSIDDTXSID70860971
ECHA ID100.231.031

Clinical Data

Drug ClassSerotonin releasing agent; Entactogen
Routes of AdministrationOral, insufflation, injection, rectal
ATC CodeNone

Pharmacokinetics

MetabolismHepatic including CYP2D6 and CYP3A4
Onset of Action20–85 minutes
Elimination Half-life(R)-MDEA: 7.5 ± 2.4 hours
(S)-MDEA: 4.2 ± 1.4 hours
Duration of Action3–5 hours
ExcretionRenal

Legal Status

Legal Status (Wikipedia Source Text)AU: S9 (Prohibited substance)
BR: Class F2 (Prohibited psychotropics)
CA: Schedule I
DE: Anlage I (Authorized scientific use only)
UK: Class A
US: Schedule I
UN: Psychotropic Schedule I

Sources and Attribution

Wikipedia Source URLhttps://en.wikipedia.org/?curid=23559034